Key Highlights

  • Unaudited Q1 FY27 revenue was $4.6 million, up 17%, and EBITDA was $1.3 million, up 31%.
  • NPAT rose 16% to $0.7 million, with the NPAT margin of 15.3% broadly flat on the prior corresponding period.
  • The TGA audit in September 2026 covered both South Granville and the new Auburn facility for the first time.
  • Cash at bank was $2.9 million at 30 September 2026, compared with $2.2 million at 30 June 2026.

Cryosite Limited (ASX:CTE) released an update on 19 October 2026 on its unaudited financial and operational performance for the quarter ended 30 September 2026 (Q1 FY27). The update also covered a Therapeutic Goods Administration (TGA) audit that, for the first time, included its new Auburn facility.

Financial results

Revenue was $4.6 million, up 17% from $3.9 million in Q1 FY26. EBITDA was $1.3 million, up 31% from $1.0 million, and the EBITDA margin was 28.5%, up 3.1 percentage points from 25.4%. EBIT was $1.0 million, up 31% from $0.8 million. NPAT rose 16% to $0.7 million from $0.6 million, and the NPAT margin was 15.3% compared with 15.4%. Operating cash flow was $1.0 million, up 40% from $0.7 million.

Cryosite said utilisation increased at South Granville and the additional volume was absorbed within existing warehouse space, systems and licences. Overheads grew well below the rate of revenue growth. Services income, its highest margin revenue line, expanded again. Cord blood renewal rates held to the long-run trend as further legacy prepaid contracts reached maturity and rolled onto annual plans.

Auburn costs and cash

Q1 FY27 was the first September quarter to carry holding costs and interest on the Auburn facility, which was drawn in November 2025, and interest expense was $0.1 million above the prior corresponding period. Cash at bank was $2.9 million at 30 September 2026, up from $2.2 million at 30 June 2026.

TGA audit and licence scope

The TGA conducted its scheduled audit in September 2026, covering the South Granville headquarters and the freehold Auburn facility for the first time. Cryosite expects Auburn to be progressed as a variation to its existing GMP licence rather than as a separate licence application, subject to TGA assessment and approval.

If approved, Cryosite would hold two TGA licensed sites four kilometres apart, each able to hold regulated product. At Auburn it could perform secondary packaging, labelling, inbound, storage and outbound activities for clinical trial materials, together with storage of cellular therapies. The audit also addressed an application to add release for supply, the final manufacturing step before a medicine may be supplied in Australia, which currently sits outside the licence scope. An outcome on both items is expected in the coming months.

Cool room extension

The extension to the largest 2°C to 8°C cool room at South Granville is complete, with racking installed during the quarter. After quality validation, the room is expected to be commissioned and available to store client product in the coming weeks. Capacity will increase by more than 120%, and the expansion was funded through operating cashflows.

Broker coverage

Alpine Capital published uncommissioned commentary on Cryosite in September 2026 after a site visit, titled The -196°C Data Centre, which compared the facilities to data centre operators. Alpine is the third firm to publish on the company within twelve months, following RaaS Advisory, which was commissioned, in October 2025 and Curran & Co, which was independent research, in June 2026.